Roche and InterMune, Inc. have entered into a definitive merger agreement whereby Roche will acquire InterMune for $8.3 billion in cash. The acquisition broadens Roche’s respiratory portfolio globally with InterMune’s lead drug pirfenidone, approved for idiopathic pulmonary fibrosis (IPF) in the EU and Canada, and is under regulatory review in the U.S. IPF is a progressive, irreversible and ultimately fatal disease characterized by progressive loss of lung function due to fibrosis, or scar...